2013-06-25 - BioVectra Named Agent of Reagent Proteins’ Products
BioVectra announced today a new agreement naming BioVectra as a non-exclusive agent of Reagent Proteins in North America and Europe. BioVectra will provide its customers access to Reagent Proteins’ unique range of over 5,000 catalog protein products; as well as actively promoting Reagent Proteins’ capabilities through its agency network and directly to its key customers, including the potential for custom projects.
“We are pleased to establish this distribution relationship with BioVectra." stated Patrick K. Lucy, Vice President, Business Development and Marketing at Pfenex Inc., “Leveraging BioVectra’s experienced business development and sales team, as well as an extensive supply chain network, provides the North American and European markets with additional access to our catalog of proteins and services.”
“BioVectra is proud to add the Reagent Proteins catalog to our portfolio of products and services including: cGMP custom manufacturing and key cGMP reagents and both biologic and synthetic API’s, from fermentation, synthesis, and natural product extraction,” Heather Delage, Director of Worldwide Sales & Marketing at BioVectra said, “This cGMP experience makes BioVectra a unique agent, able to leverage its operations and quality assurance understanding to meet the exact individual needs of biologic drug manufacturers.”
It is not uncommon for wholly owned subsidiaries to toot their own horns. Q can repeat and speak to the going forward significance of this during the CC. Also, maxdad's observations relative to Q is another reason. Jim
The ONE major fault with Questcor management is that they are not great communicators (either quantity or quality) of what's going on with the company (or now it's subsidiaries). They did do a relatively good job with their Q1 conference call in terms of providing current and some forward guidance, but even in that sense are not prone to hype of any sort. If you're a long term (months/years) you will grow to appreciate their cautious optimism as the share price slowly but surely moves to new highs and well beyond.